Nanosonics reported FY26 revenue of $203.9 million, up 3% on a reported basis but 6% higher in constant currency to $211.5 million, as its core trophon ultrasound probe disinfection platform drove growth. The company’s reported EBIT declined 10% to $16.0 million, though constant currency EBIT rose 21% to $21.6 million, reflecting a 21% increase in constant currency operating expenses to $141.4 million.
The trophon franchise, which protects 31 million patients annually, saw total unit placements rise 9% to 4,230, lifting the global installed base 6% to 39,230 devices. North America accounted for 3,880 placements, a record increase of 13%, with 1,980 units upgraded to newer models. The company estimates 8,000 original EPR devices remain for conversion. Recurring revenue, including annuities and consumables, grew 6% in constant currency to $154.8 million, while trophon-only EBIT rose 16% to $56.5 million.
CORIS, Nanosonics’ automated endoscope reprocessing system using proprietary PULSS technology, received regulatory clearances in the UK, Europe, and Australia during FY26, with a first US FDA 510(k) approval for expanded indications. The platform is now operational at five clinical sites across four markets, with a phased commercial launch planned for H1 FY27 in Australia, the UK, and Ireland, followed by H2 FY27 in the US. Capital pricing is estimated at 3–5 times trophon levels, with consumables priced 4–6 times higher per cycle.
FY27 guidance calls for constant currency revenue of $220 million to $228 million, an 8% to 12% increase from FY26, though gross profit margins are expected to compress to 74%–76% due to US tariffs, higher freight costs, and CORIS product mix. Operating expenses are projected to rise 10% to 15% to $156 million–$163 million, driven by CORIS launch activities. The company expects CORIS to contribute low single-digit millions in revenue during FY27.
Nanosonics ended FY26 with $155.2 million in cash and equivalents and no debt, while reporting a net cash outflow of $6.4 million following a $20 million share buyback and inventory builds. The company announced an on-market buyback of up to $40 million for FY27. Shares fell 14.4% to close at $3.15 following the presentation, within a 52-week range of $2.75 to $4.77.
